Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French ophthalmology company Nicox has announced it will replace its chief executive, Andreas Segerros, with current chief business officer Gavin Spencer. 28 February 2024
USA-based Pelage Pharmaceuticals, a clinical-stage regenerative medicine company developing treatments for hair loss, has closed a $16.75 million Series A financing. 27 February 2024
US clinical-stage cell therapy developer Vittoria Biotherapeutics today said that accomplished life sciences leader, Rosemary Mazanet, has joined the company as chief medical officer. 27 February 2024
Dame June Raine, chief executive of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), has today announced that she will be stepping down in the fall following five years in the role. 26 February 2024
US hematology specialist Disc Medicine today announced the appointment of Pamela Stephenson as the company’s chief commercial officer. 26 February 2024
Ophthalmology company Ocular Therapeutix has named what it describes as a ‘retina dream team’ alongside its announcement of a $325 million financing. 23 February 2024
Danish CNS specialist Lundbeck today announced a number of changes in its executive management team, first noting that Jacob Tolstrup, executive vice president, commercial operations, will leave the company no later than March 1, 2024. 23 February 2024
German family-owned drugmaker InfectoPharm Arzneimittel und Consilium GmbH has set up a further European subsidiary – this time in France. 22 February 2024
USA-based biotech Emergent BioSolutions has appointed Joseph Papa as president and chief executive (CEO), effective February 21, 2024. 22 February 2024
PolTREG, a Polish biotech developing cell therapies for autoimmune diseases, has named Daniel Shelly its chief business development officer. 21 February 2024
Cathal Friel, co-founder, substantial shareholder, and currently non-executive chairman of London-listed Poolbeg Pharma, is assuming the role of executive chairman at the company effective immediately. 15 February 2024
After four years in stealth, California, USA-based biotech Latigo Biotherapeutics today announced its emergence with a $135 million Series A financing. 14 February 2024
Privately-held French biotech StromaCare, which is developing immunotherapies through stroma modulation, today announced the appointment of Georges Rawadi as chief executive (CEO). 13 February 2024
Danish drugmaker Lundbeck has its eye on steady growth over the medium term, a strategy which new chief executive Charl van Zyl believes could be key to the firm’s future success. 12 February 2024
Spanish plasma-derived products specialist Grifols has announced that Raimon Grifols and Víctor Grifols Deu have chosen to step down from their executive functions – chief corporate officer and chief operating officer, respectively. 12 February 2024
French pharma major Sanofi has announced that Rippon Ubhi has been appointed as country lead for the UK and Ireland, taking over immediately from Jessamy Baird. 7 February 2024